Kainos Laboratories

Kainos Laboratories EPS

Delisted

The Earnings per Share (EPS) of Kainos Laboratories (4556.T) as of Nov 5, 2026 is 152.06 JPY. In the previous year, Earnings per Share (EPS) was 152.26 JPY — a change of -0.13% (lower).

EPS

152.06JPY

YoY

-0.13%

Last updated:

Earnings per Share (EPS) of Kainos Laboratories is 2025 152.06 JPY. Earnings per Share (EPS) of Kainos Laboratories was 2024 152.26 JPY. It decreases by -0.13% lower compared to the previous year.

The Kainos Laboratories EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2018
66.49 JPY
Jan 1, 2019
98.56 JPY
Jan 1, 2020
97.08 JPY
Jan 1, 2021
100.63 JPY
Jan 1, 2022
126.39 JPY
Jan 1, 2023
136.13 JPY
Jan 1, 2024
152.26 JPY
Jan 1, 2025
152.06 JPY
The Kainos Laboratories EPS history
YEAREPSYoY
152.06JPY-0.13%
152.26JPY+11.85%
136.13JPY+7.71%
126.39JPY+25.59%
100.63JPY+3.65%
97.08JPY-1.50%
98.56JPY+48.24%
66.49JPY-10.29%
74.12JPY+6.81%
69.39JPY+34.13%
51.73JPY+20.62%
42.89JPY+25.41%
34.20JPY+35.95%
25.16JPY+50.33%
16.73JPY-25.74%
22.53JPY-39.53%
37.27JPY+3,892.86%
0.93JPY-72.19%
3.36JPY-93.46%
51.33JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Kainos Laboratories Stock analysis

What does Kainos Laboratories do? Kainos Laboratories Inc develops and manufactures pharmaceuticals, diagnostic reagents, and related chemical products for distribution and import/export. The company sells its products to healthcare providers, hospitals, and medical institutions within Japan and internationally. Its core offerings include prescription medications, diagnostic tools, and chemical compounds used in medical research and treatment. The business model relies on direct sales to medical facilities and global trade of its pharmaceutical and diagnostic solutions. Kainos Laboratories Inc focuses on the Japanese market with its headquarters in Bunkyo-Ku, Tokyo-To, while also engaging in international import/export activities. The company's revenue streams come from the sale of pharmaceuticals, diagnostic reagents, and chemical products to healthcare professionals and institutions. Its product portfolio targets medical practitioners and research organizations requiring specialized diagnostic and therapeutic solutions. The company operates with 144 full-time employees dedicated to the development, manufacturing, and distribution of its products. Kainos Laboratories Inc generates income through the commercialization of its pharmaceuticals and diagnostic reagents, serving both domestic and global clients in the healthcare sector. Sales are driven by demand for medical treatments and diagnostic tools in clinical and research settings. Kainos Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kainos Laboratories stock

Earnings per Share (EPS) of Kainos Laboratories is 152.06 JPY in 2025.

Earnings per Share (EPS) of Kainos Laboratories changed from 152.26 JPY to 152.06 JPY, representing a -0.13% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Kainos Laboratories since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Kainos Laboratories

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Kainos Laboratories